[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598722":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":141,"collaborators":19,"id":143,"slug":144,"hasResults":145,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":145,"sex":151,"minAge":152,"maxAge":19,"enrollmentInfo":153,"targetDuration":19,"studyType":156,"phases":157,"briefSummary":159,"conditions":160,"keywords":175,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},{"fullName":5,"class":6},"Kelonia Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"KLN-1010","EXPERIMENTAL","Drug: KLN-1010 specified dose given once",[13],"Drug: KLN-1010",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Given at specified dose one time",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"SVP Clinical Development","CONTACT","617-223-7349","clinicaltrials@keloniatx.com",[27,48,64,81,98,115,130],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-117.97729,34.13945,{"lat":39,"lon":38},[42,46],{"name":43,"role":23,"phone":44,"phoneExt":19,"email":45},"Scott Goldsmith, MD","626-218-2405","sgoldsmith@coh.org",{"name":43,"role":47,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"facility":49,"status":29,"city":50,"state":31,"zip":51,"country":33,"countryCode":34,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Stanford University","Palo Alto","94304",{"type":36,"coordinates":53},[54,55],-122.14302,37.44188,{"lat":55,"lon":54},[58,62],{"name":59,"role":23,"phone":60,"phoneExt":19,"email":61},"Sharan Claire","650-721-4091","sharanclaire@stanford.edu",{"name":63,"role":47,"phone":19,"phoneExt":19,"email":19},"Surbhi Sidana, MD",{"facility":65,"status":29,"city":66,"state":67,"zip":68,"country":33,"countryCode":34,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Emory University Hospital","Atlanta","Georgia","30322",{"type":36,"coordinates":70},[71,72],-84.38798,33.749,{"lat":72,"lon":71},[75,79],{"name":76,"role":23,"phone":77,"phoneExt":19,"email":78},"Bryan Burton","404-778-1780","Bryan.james.burton@emory.edu",{"name":80,"role":47,"phone":19,"phoneExt":19,"email":19},"Nisha Joseph, MD",{"facility":82,"status":29,"city":83,"state":84,"zip":85,"country":33,"countryCode":34,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Providence Portland Medical Center","Portland","Oregon","97213",{"type":36,"coordinates":87},[88,89],-122.67621,45.52345,{"lat":89,"lon":88},[92,96],{"name":93,"role":23,"phone":94,"phoneExt":19,"email":95},"Laurel Brookhyser","503-215-1979","canrsrchstudies@providence.org",{"name":97,"role":47,"phone":19,"phoneExt":19,"email":19},"Stacey Lewis, MD",{"facility":99,"status":29,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"The Royal Prince Alfred","Camperdown","New South Wales","2050","Australia","AU",{"type":36,"coordinates":106},[107,108],151.17642,-33.88965,{"lat":108,"lon":107},[111],{"name":112,"role":23,"phone":113,"phoneExt":19,"email":114},"Dr. Jose Valencia-Klug","+61 2 9515 5721","jose.valencia-klug@health.nsw.gov.au",{"facility":116,"status":29,"city":117,"state":118,"zip":119,"country":103,"countryCode":104,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Peter MacCallum Cancer Centre","Melbourne","Victoria","3000",{"type":36,"coordinates":121},[122,123],144.96332,-37.814,{"lat":123,"lon":122},[126],{"name":127,"role":23,"phone":128,"phoneExt":19,"email":129},"Hannah Pahl","+61 3 8559 7851","PCCTU.HaemC@petermac.org",{"facility":131,"status":29,"city":117,"state":118,"zip":132,"country":103,"countryCode":104,"cosmosGeoPoint":133,"geoPoint":135,"contacts":136},"The Alfred Paula Fox Melanoma and Cancer Centre","3004",{"type":36,"coordinates":134},[122,123],{"lat":123,"lon":122},[137],{"name":138,"role":23,"phone":139,"phoneExt":19,"email":140},"Prof. Andrew Spencer","+61 3 9076 2000","andrew.spencer@monash.edu",{"type":142,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100598722","phase-1-a-study-to-evaluate-a-novel-gene-therapy-in-patients-with-relapsed-and-refractory-multiple-myeloma-100598722",false,"NCT07075185","A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma","inMMyCAR","Inclusion Criteria:\n\n* Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease\n* Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody\n* Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1\n* Participants must have acceptable laboratory values as defined by the protocol\n\nExclusion Criteria:\n\n* Participants must not have known central nervous system (CNS) involvement with myeloma\n* Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, or primary light chain amyloidosis\n* Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy\n* Participants cannot require systemic steroids for any condition","ALL","18 Years",{"count":154,"type":155},70,"ESTIMATED","INTERVENTIONAL",[158],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.",[161,162,163,164,165,166,167,168,169,170,171,172,173,174],"Multiple Myeloma in Relapse","Myeloma Multiple","Multiple Myeloma Progression","Neoplasms by Histologic Type","Neoplasm","Hemostatic Disorders","Vascular Disorder","Paraproteinemias","Blood Protein Disorders","Hematologic Disease and Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Disease","Gene Therapy",[176,177,178,179],"in vivo CAR-T","multiple myeloma","gene therapy","BMCA","2026-04-22",{"date":182,"type":183},"2026-04-24","ACTUAL",{"date":185,"type":183},"2025-07-16",{"date":187,"type":155},"2042-05",{"name":5,"class":6},7]